Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study

被引：0
|
作者：
Serrano, C. [1 ]
Blay, J-Y. [2 ]
Rutkowski, P. [3 ]
Gelderblom, H. [4 ]
Stacchiotti, S. [5 ]
Falcon Gonzalez, A. [6 ,7 ]
Desai, J. [8 ]
Le Cesne, A. [9 ]
Ferraresi, V. [10 ]
Palmerini, E. [11 ]
Wilky, B. A. [12 ]
Wagner, A. J. [13 ]
Bernthal, N. M. [14 ]
van de Sande, M. [15 ]
Narasimhan, S. [16 ]
Harrow, B. [16 ]
Sharma, M. G. [16 ]
Ruiz-Soto, R. [16 ]
Sherman, M. L. [16 ]
Tap, W. D. [17 ]
机构：
[1] Vall dHebron Inst Oncol, Sarcoma Translat Res, Barcelona, Spain
[2] Ctr Leon Berard, Med, Lyon, France
[3] Maria Sklodowska Curie Natl Res Inst Oncol, Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[4] Leiden Univ Med Ctr, Med Oncol, Leiden, Netherlands
[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[6] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain
[7] Inst BioMed Sevilla, Seville, Spain
[8] Peter MacCallum Canc Ctr, Clin Res, Melbourne, Vic, Australia
[9] Gustave Roussy, Inst Cancerol, Villejuif, France
[10] IRCCS Ist Nazl Tumori Regina Elena, Sarcomas & Rare Tumors Dept Unit, Rome, Italy
[11] Ist Ortoped Rizzoli, DIMES Expt Diagnost & Specialty Med, Bologna, Italy
[12] Univ Colorado, Ctr Canc, Med Oncol, Aurora, CO USA
[13] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[14] Univ Calif Los Angeles, Orthopaed Surg, Los Angeles, CA USA
[15] Leiden Univ Med Ctr, Orthoped Oncol, Leiden, Netherlands
[16] Deciphera Pharmaceut LLC, Clin Dev, Waltham, MA USA
[17] Mem Sloan Kettering Canc Ctr, Sarcoma Med Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1860
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1769P
引用
收藏
页码：S1053 / S1053
页数：1
相关论文
共 50 条
  • [41] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    Bennouna, Jaafar
    Lang, Istvan
    Valladares-Ayerbes, Manuel
    Boer, Katalin
    Adenis, Antoine
    Escudero, Pilar
    Kim, Tae-You
    Pover, Gillian M.
    Morris, Clive D.
    Douillard, Jean-Yves
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1021 - 1028
  • [42] Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study
    Xiong, Anwen
    Li, Wei
    Li, Xingya
    Fan, Yun
    Ma, Zhiyong
    Fang, Jian
    Xie, Qiang
    Zhuang, Wu
    Kang, Mafei
    Wang, Jing
    Xu, Ting
    Xu, Mo
    Zhi, Lihua
    Liu, Qing
    Wang, Ni
    Zhou, Caicun
    EUROPEAN JOURNAL OF CANCER, 2023, 190
  • [43] Open-label Phase-II-Study for Evaluating the Efficacy and Safety of Domatinostat in Combination with Avelumab in advanced, unresectable/metastatic Merkel Cell Carcinoma Patients with Progression under Anti-PD-(L) 1-Antibody Therapy - The MERKLIN 2 Study
    Terheyden, P.
    Van Akkooi, A.
    Ascierto, P. A.
    Nghiem, P.
    Henneberg, J.
    Hermann, F.
    Becker, J. C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 26 - 26
  • [44] A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen.
    Huang, Dingzhi
    Wang, Ziping
    Yu, Xinmin
    Cheng, Ying
    Wang, Jie
    Fan, Yun
    Ma, Zhiyong
    Shi, Jianhua
    Yu, Yan
    Hu, Yi
    Song, James
    Xia, Fan
    Shen, Zhirong
    Zhang, Yun
    Xu, Yingying
    Condon, Carrie
    Shi, Fangniu
    Zhou, Yunfei
    Pirzkall, Andrea
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial
    van der Kooij, Monique K.
    Verdegaal, Els M. E.
    Visser, Marten
    de Bruin, Linda
    van der Minne, Caroline E.
    Meij, Pauline M.
    Roozen, Inge C. F. M.
    Jonker, Mare A.
    van den Bosch, Shelley
    Liefers, Gerrit-Jan
    Speetjens, Frank M.
    van der Burg, Sjoerd H.
    Kapiteijn, Ellen
    BMJ OPEN, 2020, 10 (11):
  • [46] Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
    Olszewski, Adam J.
    Budde, L. Elizabeth
    Chavez, Julio
    Ghosh, Nilanjan
    Kamdar, Manali
    Lossos, Izidore S.
    Diefenbach, Catherine
    Sabry, Waleed
    Dorritie, Kathleen
    Huw, Ling-Yuh
    Pham, Song
    Jia, Ting
    Wu, Hao
    To, Iris
    Wei, Michael C.
    Assouline, Sarit
    BLOOD, 2022, 140 : 3757 - 3758
  • [47] A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer
    Ray-Coquard, Isabelle
    Haluska, Paul
    O'Reilly, Seamus
    Cottu, Paul H.
    Elit, Lorraine
    Provencher, Diane M.
    Beckmann, Matthias W.
    Bosserman, Linda D.
    Jacod, Sylvie
    Houe, Vincent
    Loberg, Robert D.
    Glaspy, John A.
    Karlan, Beth
    Slamon, Dennis J.
    Konecny, Gottfried E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally administered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC).
    Gauler, T. C.
    Fischer, B.
    Soria, J.
    Gounant, V.
    Griesinger, F.
    Krissel, H.
    Laurent, D.
    Eberhardt, W. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 412S - 412S
  • [49] A phase II study to assess the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab (MEDI4736) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Lee, Sylvia
    Villaflor, Viktoriya
    Haigentz, Missack
    Karyampudi, Kumar
    Tanamly, Susie
    Suzuki, Sam
    Gorbatchevsky, Igor
    Fardis, Maria
    Villaruz, Liza
    CANCER RESEARCH, 2018, 78 (13)
  • [50] Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Gauler, T. C.
    Besse, B.
    Meric, J. B.
    Gounant, V.
    Fischer, B.
    Overbeck, T.
    Krissel, H.
    Laurent, D.
    Soria, J. C.
    Eberhardt, W. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345